Clinical Report: Evaluating the Predictive Role of Platelet Metrics on Initial 131I Treatment Outcomes in Differentiated Thyroid Cancer Patients

Overview

This study investigates the predictive value of platelet metrics, specifically mean platelet volume (MPV), on treatment outcomes in differentiated thyroid cancer (DTC) patients undergoing initial 131I therapy. The findings indicate that MPV is independently associated with treatment response.

Background

Differentiated thyroid cancer (DTC) is the most prevalent form of thyroid cancer, with a significant proportion of patients facing recurrence and metastasis despite favorable overall prognosis. Identifying biomarkers that can predict treatment response to 131I therapy is crucial for optimizing treatment strategies and minimizing unnecessary interventions. The 2025 American Thyroid Association Guidelines highlight the importance of early assessment of treatment response to guide clinical management.

Data Highlights

Key Findings

• MPV was independently and negatively associated with non-excellent response (non-ER) to 131I therapy.
• The odds ratio for MPV predicting non-ER was 0.40 with a 95% CI of 0.28–0.58.
• Age and pre-stimulated thyroglobulin (ps-Tg) were found to influence the association between MPV and non-ER.
• The area under the ROC curve for MPV predicting non-ER was 0.664, indicating moderate predictive value.
• The optimal cutoff value for MPV was determined to be 9.95 fL, with a sensitivity of 0.595 and specificity of 0.657.

Clinical Implications

MPV may be a biomarker to identify DTC patients at risk for poor treatment response to 131I therapy.

Conclusion

The study demonstrates that MPV has predictive value for treatment response in DTC patients undergoing initial 131I therapy.

Related Resources & Content

1. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
2. The Journal of Clinical Endocrinology & Metabolism — Enhancing Recurrence Risk Assessment in Papillary Thyroid Cancer According to the 2015 ATA Guidelines
3. Frontiers in Endocrinology — Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulin
4. The Journal of Clinical Endocrinology & Metabolism — Assessing Risk Factors in Thyroid Cancer: The Complex Role of Pathologists
5. Expert Commentary: The Importance of Lymph Node Ratio and Ki-67 Levels in Papillary Thyroid Carcinoma
6. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
7. https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2022/Joint%20DTC%20Guidelines-R7-Jan11%202022.pdf
8. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer | New England Journal of Medicine
9. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial - PubMed
10. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial - ScienceDirect
11. Is radioiodine necessary for patients with low-risk differentiated thyroid cancer after thyroidectomy: a pooled analysis of ESTIMABL2 and IoN trials - PMC
12. Unmeasurable Stimulated Thyroglobulin Before Radioactive Iodine Ablation Predicts Excellent Long-Term Outcomes in Patients with Differentiated Thyroid Cancer
13. Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis - PubMed
14. 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer | European Journal of Nuclear Medicine and Molecular Imaging | Springer Nature Link
15. The Role of Mean Platelet Volume (MPV) in Thyroid Cancers: A Scoping Review - PMC